Full-year revenue guidance was updated to a new range of $7.85 billion at the low end and $8.15 billion at the high end, "increasing the midpoint to $8 billion." The full-year adjusted earnings per ...
ICON expects market conditions to remain similar through year-end, assuming persistent cancellation rates and mixed timing on biotech conversions. The company raised its full year revenue guidance to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback